Table 1.
Clinical characteristics of the participants in this study.
| Onset group | Remission group | Active group | Withdrawal group | |
|---|---|---|---|---|
| No. of patients | 61 | 64 | 43 | 25 |
| Male (N %) | 37 (60.1) | 34 (53.1) | 22 (51.1) | 15 (60) |
| Age (y) | 5.3 ± 1.8 | 7.6 ± 2.7 | 7.1 ± 3.2 | 8.6 ± 2.7 |
| Disease duration (m) | 1.1 ± 2.3 | 9.1 ± 10.9 | 11.15 ± 8.9 | 11.8 ± 11.7 |
| Current treatment | post-treatment | |||
| Without glucocorticoids | 49 (80.3) | 17 (26.6) | 8 (18.6) | 7 (28) |
| Glucocorticoids | 12(19.7) | 31 (48.4) | 26 (60.5) | 15 (60) |
| Glucocorticoids + an immuno-suppressor | 0 | 16 (25) | 9 (20.9) | 3 (12) |
| Skin involvement (N %) | 61 (100) | 64 (100) | 43 (100) | 25 (100) |
| Arthralgia (N %) | 19 (31.1) | 13 (20.3) | 5 (11.6) | 5 (20) |
| Abdominal involvement (N %) | 45 (73.8) | 27 (42.1) | 26 (60.5) | 18 (72) |
| Renal involvement (N %) | 26 (42.6) | 56 (87.5) | 32 (74.4) | 21 (84) |
| C-reactive protein (mg/L) | 17.5 ± 11.9 | 9.7 ± 5.6 | 16.5 ± 9.6 | 9.2 ± 2.9 |
| Erythrocyte sedimentation rate (mm/h) | 22.1 ± 9.4 | 13.7 ± 5.6 | 25.5 ± 14.2 | 14.2 ± 2.9 |